Stock listing

NASDAQ:CNTX Context Therapeutics Inc. Stock

Home listing (NASDAQ) of Context Therapeutics Inc.

Follow Context Therapeutics Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CNTX

$0.16 USD -0.01 (-3.8%)

Close on Nov 20, 2026

Past year -86.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.158 – $0.175 USDNov 20, 2026
Volume
1.11M sharesNov 20, 2026
Market cap
$14.70M USDAt the close on Nov 20, 2026 · price × 91.88M shares outstanding
52-week range
$0.153 – $3.62 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$440,840 USDMedian day 1.17M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Context Therapeutics Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CNTX · Home$0.16 USD-0.006 (-3.8%)1,113,620$0.161$0.175$0.158$0.166Close on Nov 20, 2026
Frankfurt:6K9€0.13 EUR-0.007 (-5.1%)—€0.093€0.13€0.093€0.137Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CNTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.16-0.006-3.8%$0.161$0.175$0.1581,113,620
$0.166-0.005-2.7%$0.171$0.176$0.1581,243,549
$0.171+0.005+3.1%$0.164$0.182$0.1532,035,575
$0.166-0.015-8.2%$0.18$0.188$0.1582,872,738
$0.181-0.017-8.7%$0.20$0.207$0.18933,085
$0.198-0.018-8.4%$0.214$0.214$0.196528,687
$0.216+0.029+15.6%$0.193$0.216$0.1861,350,719
$0.187-0.013-6.6%$0.20$0.201$0.186721,882
$0.20+0.007+3.5%$0.196$0.205$0.19765,706
$0.194+0.006+3.0%$0.192$0.204$0.181,313,308
$0.188-0.016-7.7%$0.21$0.21$0.1861,158,398
$0.204+0.009+4.9%$0.203$0.21$0.1998,240,061
$0.194-0.008-4.0%$0.205$0.21$0.191981,463
$0.202+0.013+6.8%$0.19$0.213$0.1891,291,596
$0.189-0.013-6.2%$0.203$0.203$0.1891,012,585
$0.202-0.01-4.5%$0.211$0.215$0.201,308,370
$0.211-0.023-10.0%$0.232$0.238$0.2111,526,506
$0.235-0.005-2.2%$0.232$0.242$0.221,810,190
$0.24+0.001+0.4%$0.239$0.247$0.229580,331
$0.239+0.003+1.3%$0.228$0.24$0.2151,484,900
$0.236+0.005+2.2%$0.234$0.236$0.2171,587,100
$0.231-0.013-5.3%$0.248$0.248$0.2231,165,300
$0.244+0.006+2.5%$0.238$0.253$0.228724,400
$0.238-0.006-2.5%$0.243$0.267$0.23843,400
$0.244+0.003+1.2%$0.258$0.27$0.2222,235,700
$0.241-0.015-5.9%$0.252$0.273$0.2361,337,400
$0.256-0.019-6.9%$0.272$0.272$0.25960,600
$0.275-0.03-9.8%$0.301$0.306$0.271,253,900
$0.305+0.001+0.3%$0.294$0.308$0.29503,300
$0.304+0.005+1.7%$0.30$0.31$0.298588,700
$0.299-0.014-4.5%$0.311$0.317$0.295916,600
$0.313-0.009-2.8%$0.316$0.323$0.311464,200
$0.322-0.015-4.5%$0.339$0.362$0.318898,700
$0.337+0.027+8.7%$0.31$0.34$0.311,001,300
$0.31-0.004-1.3%$0.312$0.317$0.303329,200
$0.314+0.014+4.7%$0.309$0.32$0.2991,138,300
$0.30-0.019-6.0%$0.331$0.331$0.2971,192,700
$0.319-0.007-2.1%$0.323$0.332$0.312849,400
$0.326-0.02-5.8%$0.349$0.349$0.3211,551,800
$0.346-0.025-6.7%$0.371$0.38$0.3451,324,500
$0.371-0.012-3.1%$0.38$0.389$0.363880,200
$0.383-0.006-1.5%$0.39$0.395$0.371,107,100
$0.389+0.014+3.7%$0.389$0.397$0.37539,000
$0.375+0.007+1.9%$0.379$0.388$0.364770,200
$0.368-0.015-3.9%$0.389$0.40$0.3681,209,200
$0.383+0.004+1.1%$0.374$0.388$0.361,504,300
$0.379+0.015+4.1%$0.37$0.39$0.362,128,000
$0.364+0.013+3.7%$0.364$0.383$0.3511,375,300
$0.351+0.001+0.3%$0.35$0.384$0.352,004,900
$0.35-0.016-4.4%$0.379$0.379$0.343821,800
$0.366-0.004-1.1%$0.373$0.373$0.36740,600
$0.37-0.006-1.6%$0.376$0.38$0.37642,000
$0.376+0.014+3.9%$0.36$0.378$0.351,097,500
$0.362-0.001-0.3%$0.365$0.37$0.347974,900
$0.3630.000.0%$0.371$0.375$0.3551,441,300
$0.363-0.001-0.3%$0.37$0.375$0.3511,317,500
$0.364-0.026-6.7%$0.389$0.39$0.361,814,700
$0.39+0.006+1.6%$0.385$0.399$0.3751,280,700
$0.384-0.032-7.7%$0.41$0.423$0.3813,038,000
$0.416-0.008-1.9%$0.429$0.437$0.4111,131,900
$0.424-0.011-2.5%$0.429$0.439$0.4171,029,300
$0.435-0.03-6.5%$0.47$0.475$0.3978,170,500
$0.465-0.035-7.0%$0.492$0.504$0.461,818,100
$0.50-0.02-3.8%$0.527$0.547$0.501,744,400
$0.52+0.032+6.6%$0.486$0.523$0.4831,987,500
Ticker
NASDAQ:CNTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Context Therapeutics Inc. news

Context Therapeutics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
12 in the last 12 months · 73 in all · newest Nov 10, 2026 · oldest 2021
Decks
26 decks · latest Nov 10, 2026

Where Context Therapeutics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CNTX · Home listing · This pageNASDAQUnited StatesUSD
gettex:6K9gettexGermanyEUR
LS Exchange:A3CWBULS ExchangeGermanyEUR
Lang & Schwarz:A3CWBULang & SchwarzGermanyEUR
BOATS:CNTXBOATSUnited StatesUSD
Frankfurt:6K9FrankfurtGermanyEUR
Munich:6K9MunichGermanyEUR
Stuttgart:6K9StuttgartGermanyEUR
Tradegate:6K9TradegateGermanyEUR

Valuation

Price/book 0.5× against a median of 0.8×: 2nd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$19.50M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.99

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Context Therapeutics Inc. · NASDAQ:CNTXUS$14.70M−US$19.50Mn/an/an/a0.5×n/a0.0×0.99
Atossa Therapeutics, Inc. · NASDAQ:ATOSUS$15.92M−US$4.66Mn/an/an/a0.7×n/a0.0×0.87
Quoin Pharmaceuticals. Ltd · NASDAQ:QNRXUS$15.76M−US$17.43Mn/an/an/a0.6×n/a0.0×0.68
Celularity Inc. · NASDAQ:CELUUS$15.02MUS$50.46Mn/a2.7×n/an/a−117.3%n/a1.47
NewcelX Ltd. · NASDAQ:NCELUS$14.67MUS$14.35Mn/an/an/a2.4×n/a0.1×0.89
Hepion Pharmaceuticals, Inc. · OTC:HEPAUS$14.63MUS$10.37Mn/an/an/an/an/an/a-1.02
Vectorite Biomedical, Inc. · TPEX:4170US$14.21MUS$9.16M4.9×4.9×n/a0.9×156.6%0.0×n/a
Estrella Immunopharma, Inc. · NASDAQ:ESLAUS$14.11MUS$14.01Mn/an/an/an/an/an/a1.31
Citius Pharmaceuticals, Inc. · NASDAQ:CTXRUS$13.96M−US$3.05Mn/an/an/a0.2×n/a0.0×1.71
TaiwanJ Pharmaceuticals Co., Ltd. · TPEX:6549US$13.69MUS$11.86Mn/an/an/a7.0×n/a0.0×n/a
Actuate Therapeutics, Inc. · NASDAQ:ACTUUS$13.60MUS$11.50Mn/an/an/an/an/an/a1.75
Median of the othersUS$14.42MUS$10.94M4.9×3.8×0.8×19.6%0.0×1.10

Forecasts

6 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
4.14 USD · Analysts' mean
EPS, year to Dec 2026
-0.46 · 8 analysts

Team and board

Officers

OfficerRole
Martin LehrChief Executive Officer
Jennifer Minai-AzaryChief Financial Officer
Alex LevitChief Legal Officer
Christopher BeckSVP of Operations
Jennifer DashnauSVP Technical Operations
Curtis ReinardDirector, Clinical Operations
Gregory MoylanExecutive Director, External Manufacturing
Indu RamachandranExecutive Director, Translational Medicine
Karen ChaginChief Medical Officer
Michael GirouardExecutive Director, Quality

Board

DirectorRole
Andy PasternakChairman, Independent Director
Gregory MoylanExecutive Director, External Manufacturing
Indu RamachandranExecutive Director, Translational Medicine
Jennifer Evans StaceyIndependent Director
Karen SmithIndependent Director
Linda WestIndependent Director
Luke WalkerIndependent Director
Martin LehrChief Executive Officer
Michael GirouardExecutive Director, Quality
Philip KantoffIndependent Director

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · After close+15.6%
Q2 2026Aug 5, 2026 · After close−27.3%
Q1 2026May 6, 2026 · After close−3.3%
Q4 2025Mar 25, 2026−20.1%
Q3 2025Nov 5, 2025 · After close−5.3%
Q2 2025Aug 6, 2025 · After close0.0%
Q1 2025May 7, 2025 · After close+0.0%
Q4 2024Mar 20, 2025−5.8%
Q3 2024Nov 6, 2024 · After close−5.9%
Q2 2024Aug 7, 2024 · After close+2.6%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · After close+1.1%
Q4 2023Mar 21, 2024 · Before open−7.0%
Q3 2023Nov 9, 2023 · After close−2.0%
Q2 2023Aug 9, 2023 · After close+10.6%
Q1 2023May 10, 2023 · After close−6.4%
Q4 2022Mar 22, 2023−7.6%
Q3 2022Nov 9, 2022 · After close+0.9%
Q2 2022Aug 11, 2022 · After close−3.5%
Q1 2022May 11, 2022 · After close+7.0%
Q4 2021Mar 23, 2022−1.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck37 slidesNov 10, 2026
Investor Presentation (August 2026)Investor deck37 slidesAugust 2026
Technical Presentation (June 2026)Technical31 slidesJun 15, 2026
Investor Presentation (June 2026)Investor deck44 slidesJun 15, 2026
Investor Presentation (March 2026)Investor deck35 slidesMar 23, 2026
Investor Presentation (January 2026)Investor deck40 slidesJan 8, 2026
Investor Presentation (November 2025)Investor deck40 slidesNov 5, 2025
Investor Presentation (June 2025)Investor deck39 slidesJun 2, 2025
Investor Presentation (December 2024)Investor deck43 slidesDec 2, 2024
Investor Presentation (September 2024)Investor deck42 slidesSep 23, 2024
All 26 decks
DeckKindSlidesDate
Investor Presentation (July 2024)Investor deck29 slidesJul 10, 2024
Investor Presentation (May 2024)Investor deck24 slidesMay 2, 2024
Investor Presentation (March 2024)Investor deck23 slidesMar 6, 2024
Investor Presentation (October 2023)Investor deck31 slidesOct 31, 2023
Investor Presentation (August 2023)Investor deck26 slidesAug 7, 2023
Investor Presentation (March 2023)Investor deck30 slidesMar 22, 2023
Investor Presentation (February 2023)Investor deck40 slidesFeb 6, 2023
Investor Presentation (January 2023)Investor deck39 slidesJan 4, 2023
Technical Presentation (December 2022)Technical41 slidesDec 1, 2022
Investor Presentation (November 2022)Investor deck28 slidesNov 9, 2022
Investor Presentation (September 2022)Investor deck25 slidesSep 27, 2022
Investor Presentation (August 2022)Investor deck26 slidesAug 2, 2022
Investor Presentation (January 2022)Investor deck22 slidesJan 10, 2022
IPO Roadshow (October 2021)IPO roadshow45 slidesOct 18, 2021
IPO Roadshow (July 2021)IPO roadshow41 slidesJul 12, 2021
IPO Roadshow (July 2021)IPO roadshow42 slidesJul 2, 2021

Open Decks

IPO

Priced at US$5.00 a share on Oct 19, 2021.

Price
US$5.00 a share
Shares offered
5,000,000 shares of common stock
Offering size
US$25 million
Underwriters' option
Up to 750,000 more shares
Underwriter
ThinkEquity
Shares delivered
On or about Oct 22, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceMar 22, 2021
Filed publiclyMay 27, 2021
Amended 7 timesNewest Oct 18, 2021
Shares registered with an exchangeJul 23, 2021
Declared effective by the SECOct 19, 2021
Final prospectus, with the priceOct 20, 2021

Filings

FilingFiled
424B4 · ProspectusOct 20, 2021
EFFECT · Notice that a registration is effectiveOct 19, 2021
FWP · Free writing prospectusOct 18, 2021
S-1/A · Registration statement, amendedOct 18, 2021
CORRESP · Letter to the SECOct 15, 2021
CORRESP · Letter to the SECOct 15, 2021
FWP · Free writing prospectusSep 29, 2021
S-1/A · Registration statement, amendedSep 29, 2021
CORRESP · Letter to the SECSep 24, 2021
FWP · Free writing prospectusSep 24, 2021
All 38 filings
FilingFiled
S-1/A · Registration statement, amendedSep 24, 2021
UPLOAD · Letter from the SECSep 22, 2021
FWP · Free writing prospectusSep 13, 2021
S-1/A · Registration statement, amendedSep 13, 2021
CORRESP · Letter to the SECAug 2, 2021
CORRESP · Letter to the SECAug 2, 2021
CERT · Exchange's certificate of listingJul 27, 2021
8-A12B · Registration of shares for listing on an exchangeJul 23, 2021
CORRESP · Letter to the SECJul 23, 2021
S-1/A · Registration statement, amendedJul 23, 2021
CORRESP · Letter to the SECJul 23, 2021
CORRESP · Letter to the SECJul 23, 2021
UPLOAD · Letter from the SECJul 12, 2021
FWP · Free writing prospectusJul 12, 2021
FWP · Free writing prospectusJul 12, 2021
FWP · Free writing prospectusJul 2, 2021
S-1/A · Registration statement, amendedJul 2, 2021
CORRESP · Letter to the SECJul 1, 2021
CORRESP · Letter to the SECJul 1, 2021
S-1/A · Registration statement, amendedJun 16, 2021
UPLOAD · Letter from the SECJun 4, 2021
CORRESP · Letter to the SECMay 27, 2021
S-1 · Registration statementMay 27, 2021
UPLOAD · Letter from the SECMay 20, 2021
DRS/A · Draft registration statement, amendedMay 3, 2021
DRSLTR · Letter to the SEC with a draftApr 30, 2021
UPLOAD · Letter from the SECApr 22, 2021
DRS · Draft registration statementMar 22, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Oct 20, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2017FY2016
Revenue000000000
Cost of revenue124.7K52.7K12.0K9.27K00
Gross profit-124.7K-52.7K-12.0K-9.27K00
Research and development31.9M22.7M17.8M7.09M3.81M1.64M2.41M17.6M27.8M
Selling, general and administrative7.85M7.22M7.29M7.79M3.63M930.7K2.97M24.0M33.2M
Operating income-39.7M-29.9M-25.1M-15.4M-10.5M-2.57M-5.38M-24.1M-33.2M
Depreciation and amortization16.3K10.9K12.0K9.27K02.57K5.38K21.0K36.0K
EBITDA-39.7M-29.9M-25.1M-15.4M-10.5M-2.57M-5.37M-24.0M-33.2M
Interest expense547.3K64.2K661.2K1.10M00
Income before tax-36.1M-26.7M-24.0M-14.8M-10.5M6.64M-6.38M-25.1M-37.7M
Income tax0000001.10M-441.0K0
Net income-36.1M-26.7M-24.0M-14.8M-10.5M6.64M-7.48M-24.6M-37.7M
Earnings per share, basic-0.38-0.46-1.50-0.93-3.693.07-0.68
Earnings per share, diluted-0.38-0.46-1.50-0.93-3.69-3.96

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2017FY2016
Cash and equivalents66.0M94.4M14.4M35.5M49.6M290.7K226.6K60.7M16.2M
Current assets68.4M97.9M16.0M37.9M51.3M299.3K239.6K61.3M17.1M
Property, plant and equipment29.7K12.0K15.5K27.6K029.0K60.0K
Goodwill1.40M1.40M
Total assets68.5M98.1M16.1M38.0M51.3M467.3K273.5K68.3M24.0M
Accounts payable2.53M1.45M2.38M936.3K1.83M2.71M2.07M2.02M1.69M
Current liabilities8.02M2.75M4.19M3.21M3.03M9.55M24.1M4.97M4.91M
Long-term debt69.0K390.0K1.96M
Total debt112.1K219.4K55.1K5.95M21.8M
Total liabilities8.02M2.86M4.19M3.21M3.03M9.62M24.2M9.38M10.9M
Shareholders' equity60.5M95.3M11.9M34.8M48.3M-16.9M-24.0M59.0M13.1M
Shares outstanding91.9M89.7M16.0M16.0M16.0M331.8K11.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2017FY2016
Cash from operations-26.4M-14.6M-21.0M-13.5M-8.80M-1.03M-2.84M-22.3M-30.6M
Capital spending-33.9K-7.32K0-36.8K000-28.0K-28.0K
Free cash flow-26.4M-14.6M-21.0M-13.6M-8.80M-1.03M-2.84M-22.4M-30.6M
Cash from investing-2.03M-14.8M0-536.8K-250.0K0-250.0K-28.0K-28.0K
Cash from financing-15.3K109.3M0-102.1K58.4M1.15M1.96M66.8M44.2M
Change in cash-28.4M80.0M-21.0M-14.2M49.3M114.4K-878.7K44.4M13.6M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 10, 2026Current reportSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2026Big-stake noticeSEC
8-K · Current reportAug 5, 2026Current reportSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportJul 31, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 31, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 27, 2026Big-stake noticeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
8-K · Current reportJun 26, 2026Meeting outcomeSEC
8-K · Current reportJun 15, 2026Current reportSEC
8-K · Current reportMay 18, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 8, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 6, 2026Quarterly reportSEC
8-K · Current reportMay 1, 2026Current reportSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 17, 2026Meeting noticeSEC
8-K · Current reportApr 2, 2026Current reportSEC
S-8 · Registration statement for employee plansMar 23, 2026Offer documentSEC
8-K · Current reportMar 23, 2026Current reportSEC
10-K · Annual reportMar 23, 2026Annual reportSEC
8-K · Current reportMar 13, 2026Current reportSEC
8-K · Current reportFeb 27, 2026Current reportSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 3, 2026Big-stake noticeSEC
8-K · Current reportJan 8, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 5, 2025Current reportSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportOct 24, 2025Material contractSEC
424B5 · ProspectusOct 24, 2025Offer documentSEC
8-K · Current reportOct 20, 2025Current reportSEC
8-K · Current reportSep 2, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
8-K · Current reportJun 12, 2025Meeting outcomeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2025Insider tradeSEC
8-K · Current reportJun 2, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 9, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2025Quarterly reportSEC
ARS · Annual report to shareholdersApr 15, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 15, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 15, 2025Meeting noticeSEC
8-K · Current reportApr 9, 2025Current reportSEC
PRE 14A · Preliminary proxy statementApr 4, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 20, 2025Offer documentSEC
10-K · Annual reportMar 20, 2025Annual reportSEC
8-K · Current reportFeb 28, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 27, 2025Big-stake noticeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 14, 2025Insider tradeSEC
8-K · Current reportJan 14, 2025Current reportSEC
8-K · Current reportJan 13, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeJan 8, 2025Big-stake noticeSEC
8-K · Current reportDec 23, 2024Current reportSEC
8-K · Current reportDec 2, 2024Material contractSEC
424B5 · ProspectusDec 2, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 15, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
CORRESP · Letter to the SECNov 12, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 12, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 6, 2024Big-stake noticeSEC
S-3 · Registration statementNov 6, 2024Offer documentSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportSep 23, 2024Material contractSEC
8-K · Current reportSep 17, 2024Meeting outcomeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 5, 2024Insider tradeSEC
8-K · Current reportSep 4, 2024Management or board changeSEC
10-Q · Quarterly reportAug 7, 2024Quarterly reportSEC
4 · Change in ownershipAug 1, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 1, 2024Insider tradeSEC
DEFA14A · Additional proxy materialJul 24, 2024Meeting noticeSEC
DEF 14A · Proxy statementJul 24, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementJul 12, 2024Meeting noticeSEC
8-K · Current reportJul 10, 2024Material contractSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Meeting outcomeSEC
SC 13G · Big-stake noticeJun 5, 2024Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJun 3, 2024Other filingsSEC
424B3 · ProspectusMay 31, 2024Offer documentSEC
CORRESP · Letter to the SECMay 29, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 29, 2024Other filingsSEC
SC 13G · Big-stake noticeMay 24, 2024Big-stake noticeSEC
S-3 · Registration statementMay 24, 2024Offer documentSEC
DMay 16, 2024Other filingsSEC
SC 13G · Big-stake noticeMay 13, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeMay 10, 2024Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2024Quarterly reportSEC
8-K · Current reportMay 2, 2024Material contractSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
8-K · Current reportApr 1, 2024Current reportSEC
4 · Change in ownershipMar 22, 2024Insider tradeSEC
4 · Change in ownershipMar 22, 2024Insider tradeSEC
4 · Change in ownershipMar 22, 2024Insider tradeSEC
S-8 · Registration statement for employee plansMar 21, 2024Offer documentSEC
10-K · Annual reportMar 21, 2024Annual reportSEC
8-K · Current reportMar 21, 2024Current reportSEC
8-K · Current reportMar 6, 2024Material contractSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeJan 5, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportOct 31, 2023Current reportSEC
10-Q · Quarterly reportAug 9, 2023Quarterly reportSEC
8-K · Current reportAug 7, 2023Current reportSEC
8-K · Current reportJun 20, 2023Current reportSEC
8-K · Current reportJun 2, 2023Meeting outcomeSEC
4 · Change in ownershipMay 31, 2023Insider tradeSEC
4 · Change in ownershipMay 31, 2023Insider tradeSEC
4 · Change in ownershipMay 31, 2023Insider tradeSEC
4 · Change in ownershipMay 31, 2023Insider tradeSEC
10-Q · Quarterly reportMay 10, 2023Quarterly reportSEC
DEFA14A · Additional proxy materialApr 6, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 6, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementMar 27, 2023Meeting noticeSEC
S-8 · Registration statement for employee plansMar 22, 2023Offer documentSEC
10-K · Annual reportMar 22, 2023Annual reportSEC
8-K · Current reportMar 22, 2023ResultsSEC
4 · Change in ownershipFeb 21, 2023Insider tradeSEC
4 · Change in ownershipFeb 14, 2023Insider tradeSEC
4 · Change in ownershipFeb 14, 2023Insider tradeSEC
4 · Change in ownershipFeb 14, 2023Insider tradeSEC
SC 13G · Big-stake noticeFeb 14, 2023Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2023Insider tradeSEC
4 · Change in ownershipFeb 6, 2023Insider tradeSEC
8-K · Current reportFeb 6, 2023Current reportSEC
4 · Change in ownershipJan 30, 2023Insider tradeSEC
8-K · Current reportJan 27, 2023Current reportSEC
4 · Change in ownershipJan 23, 2023Insider tradeSEC
4 · Change in ownershipJan 18, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJan 10, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 9, 2023Big-stake noticeSEC
8-K · Current reportJan 4, 2023Current reportSEC
4 · Change in ownershipDec 19, 2022Insider tradeSEC
4 · Change in ownershipDec 19, 2022Insider tradeSEC
4 · Change in ownershipDec 12, 2022Insider tradeSEC
8-K · Current reportDec 8, 2022Current reportSEC
8-K · Current reportDec 1, 2022Current reportSEC
EFFECT · Notice that a registration is effectiveNov 17, 2022Other filingsSEC
CORRESP · Letter to the SECNov 14, 2022Other filingsSEC
424B3 · ProspectusNov 14, 2022Offer documentSEC
UPLOAD · Letter from the SECNov 14, 2022Other filingsSEC
EFFECT · Notice that a registration is effectiveNov 14, 2022Other filingsSEC
POS AM · Amendment to an effective registrationNov 9, 2022Offer documentSEC
S-3 · Registration statementNov 9, 2022Offer documentSEC
424B3 · ProspectusNov 9, 2022Offer documentSEC
8-K · Current reportNov 9, 2022Current reportSEC
10-Q · Quarterly reportNov 9, 2022Quarterly reportSEC
SC 13G · Big-stake noticeOct 27, 2022Big-stake noticeSEC
424B3 · ProspectusSep 27, 2022Offer documentSEC

This page holds 200 of 309 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Context Therapeutics Inc.’s releases · as of Nov 6, 2026

Common shares
91,879,177
Fully diluted
91,879,177

Fully diluted

LineSharesAs of
Common shares91,879,177Nov 6, 2026

Share count over time

CountShares
Nov 6, 202691,879,177

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Nextech Invest Ltd.7.42M8.1%US$2.23MSep 30, 2026
Deep Track Capital, LP7.42M8.1%US$2.23MSep 30, 2026
Soleus Capital Management, L.P.7.06M7.7%US$2.12MSep 30, 2026
BlackRock6.14M6.7%US$1.84MSep 30, 2026
Vanguard4.52M4.9%US$1.36MSep 30, 2026
Avidity Partners Management LP4.06M4.4%US$1.22MSep 30, 2026
AQR Capital Management LLC2.93M3.2%US$881KSep 30, 2026
TCG Crossover Management, LLC2.68M2.9%US$806KSep 30, 2026
Acadian Asset Management LLC1.99M2.2%US$597KSep 30, 2026
Geode Capital1.9M2.1%US$570KSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
State Street1.46M1.6%US$437KSep 30, 2026
Verdad Advisers, LP1.13M1.2%US$340KSep 30, 2026
Citadel996K1.1%US$299KSep 30, 2026
Renaissance Technologies967K1.1%US$291KSep 30, 2026
Luminus Management LLC914K0.99%US$274KSep 30, 2026
ADAR1 Capital Management, LLC751K0.82%US$226KSep 30, 2026
Russell Investments Group, Ltd.671K0.73%US$202KSep 30, 2026
Northern Trust623K0.68%US$187KSep 30, 2026
UBS525K0.57%US$157KSep 30, 2026
Goldman Sachs416K0.45%US$125KSep 30, 2026
Squarepoint Ops LLC298K0.32%US$89,664Sep 30, 2026
Barclays298K0.32%US$89,475Sep 30, 2026
Cantor Fitzgerald, L. P.260K0.28%US$78,104Sep 30, 2026
MYDA Advisors LLC250K0.27%US$75,100Sep 30, 2026
Landscape Capital Management, L.L.C.241K0.26%US$72,490Sep 30, 2026
Pathstone Holdings, LLC229K0.25%US$68,797Sep 30, 2026
Schwab228K0.25%US$68,446Sep 30, 2026
Timothy G. Youngquist 2020 Irrevocable Trust198K0.22%US$59,595Sep 30, 2026
Nuveen181K0.20%US$54,408Sep 30, 2026
BNY148K0.16%US$44,543Sep 30, 2026
New York State Common Retirement Fund135K0.15%US$40,644Sep 30, 2026
HighTower Advisors, LLC126K0.14%US$37,840Sep 30, 2026
Private Advisor Group, LLC126K0.14%US$37,806Sep 30, 2026
XTX Topco Ltd111K0.12%US$33,315Sep 30, 2026
Clear Harbor Asset Management, LLC92,8040.10%US$27,878Sep 30, 2026
Bank of America91,7660.10%US$27,530Sep 30, 2026
DWS79,4220.09%US$23,827Sep 30, 2026
T. Rowe Price77,5380.08%US$24,000Sep 30, 2026
Natixis73,9740.08%US$22,592Sep 30, 2026
Rhumbline Advisers65,2290.07%US$19,566Sep 30, 2026
Invesco62,0780.07%US$18,648Sep 30, 2026
AllianceBernstein59,0000.06%US$17,700Sep 30, 2026
Cerity Partners LLC55,1520.06%US$16,568Sep 30, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.45,1930.05%US$13,576Sep 30, 2026
Morgan Stanley44,3310.05%US$13,317Sep 30, 2026
BNP Paribas44,1590.05%US$13,265Sep 30, 2026
JPMorgan44,1280.05%US$14,077Sep 30, 2026
Ieq Capital, LLC41,4180.05%US$12,442Sep 30, 2026
Fidelity34,8360.04%US$10,465Sep 30, 2026
Mercer Global Advisors Inc30,9910.03%US$9,310Sep 30, 2026

This page holds 50 of 83 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund2.82M3.1%US$1.56MJun 30, 2026
iShares Russell 2000 ETF2.33M2.5%US$1.29MJun 30, 2026
Franklin Biotechnology Discovery Fund1.4M1.5%US$838KJul 31, 2026
Fidelity Small Cap Index Fund1.01M1.1%US$604KJul 31, 2026
iShares Russell 2000 Growth ETF875K0.95%US$485KJun 30, 2026
Vanguard Extended Market Index Fund521K0.57%US$289KJun 30, 2026
iShares Micro-Cap ETF313K0.34%US$173KJun 30, 2026
Fidelity Extended Market Index Fund250K0.27%US$713KMay 31, 2026
Schwab Small-Cap Index Fund228K0.25%US$137KJul 31, 2026
Master Small Cap Index Series203K0.22%US$113KJun 30, 2026
All 49 holders
HolderSharesOf the companyValueAs of
Nuveen Small Cap Blend Index Fund126K0.14%US$75,235Jul 31, 2026
EQ/2000 Managed Volatility Portfolio104K0.11%US$57,459Jun 30, 2026
Fidelity Total Market Index Fund97,6150.11%US$278KMay 31, 2026
Fidelity Small Cap Growth Index Fund88,3950.10%US$48,962Jun 30, 2026
Fidelity Series Total Market Index Fund72,6160.08%US$207KMay 31, 2026
Fidelity Nasdaq Composite Index Fund63,7050.07%US$182KMay 31, 2026
Avantis U.S. Small Cap Equity ETF54,0620.06%US$154KMay 31, 2026
Vanguard Institutional Total Stock Market Index Fund53,1250.06%US$29,426Jun 30, 2026
Small Cap Index Fund48,8350.05%US$27,050Jun 30, 2026
Global X Russell 2000 ETF44,4960.05%US$26,671Jul 31, 2026
Vanguard Balanced Index Fund42,4440.05%US$23,510Jun 30, 2026
Small-Cap Index Portfolio41,1530.04%US$22,795Jun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio40,5000.04%US$22,433Jun 30, 2026
EQ/Small Company Index Portfolio29,5000.03%US$16,340Jun 30, 2026
EQ/AB Small Cap Growth Portfolio29,5000.03%US$16,340Jun 30, 2026
NVIT Small Cap Index Fund21,5930.02%US$11,960Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio21,2540.02%US$11,773Jun 30, 2026
1290 VT Micro Cap Portfolio21,0720.02%US$11,672Jun 30, 2026
BlackRock Small Cap Index V.I. Fund19,3150.02%US$10,699Jun 30, 2026
DWS Small Cap Index VIP14,4270.02%US$7,991Jun 30, 2026
T. Rowe Price Small-Cap Index Fund14,2140.02%US$7,873Jun 30, 2026
EQ/Morgan Stanley Small Cap Growth Portfolio13,6280.01%US$7,549Jun 30, 2026
Nationwide Small Cap Index Fund12,6690.01%US$7,594Jul 31, 2026
SA Small Cap Index Portfolio11,2020.01%US$6,714Jul 31, 2026
CVT Russell 2000 Small Cap Index Portfolio8,455<0.01%US$4,683Jun 30, 2026
EQ/Franklin Small Cap Value Managed Volatility Portfolio8,375<0.01%US$4,639Jun 30, 2026
PD Small-Cap Growth Index Portfolio8,279<0.01%US$4,586Jun 30, 2026
Victory Extended Market Index Fund7,457<0.01%US$4,470Jul 31, 2026
Venerable Small Cap Index Fund7,450<0.01%US$4,127Jun 30, 2026
SmallCap Growth Fund I7,142<0.01%US$4,281Jul 31, 2026
Total Stock Market Index Trust1,719<0.01%US$952Jun 30, 2026
Ultra Small Cap Profund1,199<0.01%US$719Jul 31, 2026
Russell 2000 2x Strategy Fund501<0.01%US$278Jun 30, 2026
Profund Vp Ultra Small Cap383<0.01%US$212Jun 30, 2026
Profund Vp Small Cap250<0.01%US$138Jun 30, 2026
Russell 2000 Fund231<0.01%US$128Jun 30, 2026
Russell 2000 1.5x Strategy Fund138<0.01%US$76Jun 30, 2026
Small-Cap Profund79<0.01%US$47Jul 31, 2026
Russell 2000(R) 1.5x Strategy Fund26<0.01%US$14Jun 30, 2026

Big stakes

StakeStakeSharesDateFiling
Avidity Partners Management LP8.70%8.3MMar 31, 2026Schedule 13G
Deep Track Capital, LP8.27%7.42MMar 31, 2025Schedule 13G
Soleus Capital Master Fund, L.P.7.60%6.96MMar 31, 2026Schedule 13G
BlackRock, Inc.6.70%6.17MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Karen Smith
Other companies: Skye Bioscience, Inc. (Director · Since at least Jul 2, 2024); Sangamo Therapeutics, Inc. (Director · Since at least Jun 26, 2018); Aurinia Pharmaceuticals Inc (Director · Aug 18, 2023 – Nov 21, 2024 · Past); Quince Therapeutics, Inc. (Chief Medical Officer · May 19, 2022 – Feb 1, 2023 · Past); Tourmaline Bio Inc. (Director · May 16, 2022 – Jun 13, 2023 · Past); Emergent BioSolutions Inc. (EVP, Chief Medical Officer · May 21, 2020 – May 7, 2021 · Past); Antares Pharma Inc (Director · Mar 1, 2019 – May 24, 2022 · Past); Acceleron Pharma Inc (Director · Nov 15, 2017 – Nov 19, 2021 · Past); Sucampo Pharmaceuticals Inc (Director · Jul 15, 2017 – Feb 13, 2018 · Past); Jazz Pharmaceuticals plc (EVP, R&D and CMO · Apr 13, 2015 – Mar 5, 2018 · Past)
Independent Director · Since at least Sep 4, 2024
Luke Walker
Other companies: Zentalis Pharmaceuticals, Inc. (Director · Since at least May 24, 2024); Harpoon Therapeutics Inc (Chief Medical Officer · Oct 3, 2022 – Mar 11, 2024 · Past)
Director · Since at least Sep 4, 2024
Linda West
Other companies: Galera Therapeutics, Inc. (Director · Mar 31, 2020 – Jul 1, 2023 · Past)
Independent Director · Since at least Oct 19, 2021
Philip W Kantoff
Other companies: ESSA Pharma Inc (Director · Sep 13, 2022 – Mar 25, 2024 · Past)
Director · Since at least Oct 19, 2021
Alex LevitChief Legal Officer · Since at least Nov 5, 2026
Andy PasternakChairman, Independent Director · Since at least Jan 13, 2025
Christopher BeckSVP of Operations · Since at least Nov 5, 2026
Curtis ReinardDirector, Clinical Operations · Since at least Nov 5, 2026
Erin ZebrowskiDirector, Clinical Sciences · Nov 4, 2026 – Nov 4, 2026 · Past
Gregory MoylanExecutive Director, External Manufacturing · Since at least Nov 5, 2026
All 21 people
PersonSeat
Indu RamachandranExecutive Director, Translational Medicine · Since at least Nov 5, 2026
Jennifer DashnauSVP Technical Operations · Since at least Nov 5, 2026
Jennifer Evans StaceyIndependent Director · Since at least Nov 5, 2026
Jennifer Minai-AzaryChief Financial Officer · Since at least Sep 9, 2026
Karen ChaginChief Medical Officer · Since at least Jun 9, 2025
Martin LehrChief Executive Officer · Since at least Aug 19, 2022
Mary SpharExecutive Assistant & Office Manager · Nov 4, 2026 – Nov 4, 2026 · Past
Michael GirouardExecutive Director, Quality · Since at least Nov 5, 2026
Philip KantoffIndependent Director · Since at least Nov 4, 2026
Ullmann Claudio DanskyChief Medical Officer · Aug 1, 2024 – Feb 13, 2025 · Past
William F RencherHead of CMC and Regulatory · Oct 19, 2021 – Oct 19, 2021 · Past

Open People

Log in to ask 6ix AI your own questions about Context Therapeutics Inc.